Founded in 2009, PolyPhotonix is a multi-award winning bio-photonic research company developing light therapy treatments for macular eye disease as well as other medical conditions. In just six years PolyPhotonix has grown from one employee with an idea, to manufacturing a phototherapy eye mask that independent health economists working with the NHS estimate could save on adoption of the technology in excess of £1 billion a year.
PolyPhotonix has developed a home-based, non-invasive, monitored treatment for one of the principal causes of blindness in the western world, Diabetic Retinopathy (DR) and Diabetic Macular Oedema (DMO). The Noctura 400 Sleep Mask, offers a novel and innovative treatment for Diabetic patients with these serious sight complications, and will significantly change the patient experience and cost basis compared with current treatments. DR and DMO are common and serious eye complications which can lead to blindness and develop in 90% of Type 1 Diabetics and 67% of Type 2 sufferers.
The Noctura 400® Sleep Mask is designed to be worn at night, to deliver a precise dose of light therapy during a patient’s normal hours of sleep. The treatment works on the principle of preventing the rods in the eye from dark adaptation, which reduces the oxygen demand of the eye at night, preventing hypoxia and the compromised blood vessel proliferation that can result in the retina, causing the DR and DMO.
The Pod contains the light sources which, when worn, emit light into the eyes through closed eyelids. Nothing is inserted into the eyes – the treatment is non-invasive. The mask is programmed to administer the correct dose of light each night as part of a continuing therapy.